Immunohistochemistry Breast Markers Audit

Quality assurance activity for laboratories reporting immunohistochemistry (IHC) and in-situ hybridization (ISH) breast markers through an audit of clinical results. There is no technical component to this survey, but it comprises online submission of the hormone receptor and HER2 status for each case of early invasive primary (not stage 4 disease) breast carcinoma. 50-100 samples are required for assessment. Laboratories providing less than 50 samples will not qualify for assessment.